TA239 Breast cancer (metastatic) - fulvestrant: review decision November 2014 information
History
A list of downloadable documents created during development.
Background information
-
-
TA239 Breast cancer (metastatic) - fulvestrant: Appendix A - GE decision paper - November 2014
-
-
TA239 Breast cancer (metastatic) - fulvestrant: review proposal - August 2014 information
-
TA239 Breast cancer (metastatic) - fulvestrant: appendix A - matrix of stakeholders
-
TA239 Breast cancer (metastatic) - fulvestrant: appendix A - matrix of stakeholders (PDF 99 KB)
-
TA239 Breast cancer (metastatic) - fulvestrant: appendix B - proposal paper presented to the Institute's Guidance Executive
-
Breast cancer (metastatic) - fulvestrant: Equality Impact Assessment
-
Breast cancer (metastatic) - fulvestrant: Equality Impact Assessment
-
Breast cancer (metastatic) - fulvestrant: Equality Impact Assessment (PDF 76 KB)
Breast cancer (metastatic) - fulvestrant: final appraisal determination
-
Breast cancer (metastatic) - fulvestrant: final appraisal determination information
-
Breast cancer (metastatic) - fulvestrant: final appraisal determination document
-
Breast cancer (metastatic) - fulvestrant: final appraisal determination document (PDF 307 KB)
-
Breast cancer (metastatic) - fulvestrant: response to consultee, commentator and public comments on the Appraisal Consultation Document (ACD)
-
-
Breast cancer (metastatic) - fulvestrant: consultee and commentator comments on the ACD
-
Breast cancer (metastatic) - fulvestrant: AstraZeneca
-
Breast cancer (metastatic) - fulvestrant: AstraZeneca (PDF 669 KB)
-
Breast cancer (metastatic) - fulvestrant: Breakthrough Breast Cancer
-
Breast cancer (metastatic) - fulvestrant: Breakthrough Breast Cancer (PDF 35 KB)
-
Breast cancer (metastatic) - fulvestrant: Royal College of Nursing
-
Breast cancer (metastatic) - fulvestrant: Royal College of Nursing (PDF 57 KB)
-
Breast cancer (metastatic) - fulvestrant: joint comment from National Cancer Research Institute, Royal College of Physician, Royal College of Radiologists, Association of Cancer Physicians and Joint Collegiate Council for Oncology
-
-
Breast cancer (metastatic) - fulvestrant: South Staffordshire PCT
-
Breast cancer (metastatic) - fulvestrant: South Staffordshire PCT (PDF 8.2 KB)
-
Breast cancer (metastatic) - fulvestrant: Commissioning Support Appraisals Service
-
Breast cancer (metastatic) - fulvestrant: Commissioning Support Appraisals Service (PDF 264 KB)
-
Breast cancer (metastatic) - fulvestrant: comments on the ACD received from the public through the NICE website
-
Breast cancer (metastatic) - fulvestrant: appraisal consultation
-
Breast cancer (metastatic) - fulvestrant: appraisal consultation
-
Breast cancer (metastatic) - fulvestrant: appraisal consultation document information
-
Breast cancer (metastatic) - fulvestrant: evaluation report
-
Breast cancer (metastatic) - fulvestrant: pre-meeting briefing
-
Breast cancer (metastatic) - fulvestrant: pre-meeting briefing (PDF 137 KB)
-
Breast cancer (metastatic) - fulvestrant: Evidence Review Group report
-
Breast cancer (metastatic) - fulvestrant: Evidence Review Group report (PDF 1.77 MB)
-
Breast cancer (metastatic) - fulvestrant: Evidence Review Group report - addendum
-
Breast cancer (metastatic) - fulvestrant: Evidence Review Group report - addendum (PDF 102 KB)
-
Breast cancer (metastatic) - fulvestrant: Evidence Review Group report - factual accuracy check
-
-
Breast cancer (metastatic) - fulvestrant: manufacturer submission
-
Breast cancer (metastatic) - fulvestrant: manufacturer submission from AstraZeneca
-
Breast cancer (metastatic) - fulvestrant: manufacturer submission from AstraZeneca (PDF 4.78 MB)
-
Breast cancer (metastatic) - fulvestrant: NICE clarification letter
-
Breast cancer (metastatic) - fulvestrant: NICE clarification letter (PDF 77 KB)
-
Breast cancer (metastatic) - fulvestrant: manufacturer response to the NICE clarification letter
-
-
Breast cancer (metastatic) - fulvestrant: request for further clarification
-
Breast cancer (metastatic) - fulvestrant: request for further clarification (PDF 142 KB)
-
Breast cancer (metastatic) - fulvestrant: manufacturer response to further clarification request
-
-
Breast cancer (metastatic) - fulvestrant: patient group, professional group and NHS organisation submission statements
-
Breast cancer (metastatic) - fulvestrant: joint submission from Breast Cancer Care, Breakthrough Breast Cancer, Macmillan Cancer Support and Breast Cancer Campaign
-
-
Breast cancer (metastatic) - fulvestrant: submission from Royal College of Pathologists
-
Breast cancer (metastatic) - fulvestrant: submission from Royal College of Pathologists (PDF 78 KB)
-
Breast cancer (metastatic) - fulvestrant: joint submission from NCRI/RCP/RCR/ACP/JCCO
-
Breast cancer (metastatic) - fulvestrant: joint submission from NCRI/RCP/RCR/ACP/JCCO (PDF 100 KB)
-
Breast cancer (metastatic) - fulvestrant: expert statement from Hecht
-
Breast cancer (metastatic) - fulvestrant: expert statement from Hecht (PDF 80 KB)
Breast cancer (metastatic) - fulvestrant: response to consultee and commentator comments on provisional matrix
-
Breast cancer (metastatic) - fulvestrant: response to consultee and commentator comments on provisional matrix
-
Breast cancer (metastatic) - fulvestrant: consultation comments table
-
Breast cancer (metastatic) - fulvestrant: consultation comments table
-
Breast cancer (metastatic) - fulvestrant: consultation comments table (PDF 69 KB)
Breast cancer (metastatic) - fulvestrant: final matrix
-
Breast cancer (metastatic) - fulvestrant: final matrix
-
Breast cancer (metastatic) - fulvestrant: final matrix (PDF 32 KB)
Breast cancer (metastatic) - fulvestrant: final scope
-
Breast cancer (metastatic) - fulvestrant: final scope
-
Breast cancer (metastatic) - fulvestrant: final scope (PDF 29 KB)
Breast cancer (metastatic) - fulvestrant: provisional matrix (pre-referral) - November 2009
-
Breast cancer (metastatic) - fulvestrant: provisional matrix (pre-referral) - November 2009
-
Breast cancer (metastatic) - fulvestrant: draft scope for consultation (pre-referral) - November 2009
-
Breast cancer (metastatic) - fulvestrant: draft scope for consultation (pre-referral) - November 2009
-